Zobrazeno 1 - 10
of 1 529
pro vyhledávání: '"RC254-282"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundHyperprogressive disease (HPD) is a distinct pattern of rapid tumor progression observed in patients with cancer who are undergoing immune checkpoint inhibitor therapy. Despite the growing evidence, a universal definition of HPD remains to
Autor:
Marc Gillig, Graeme Lambert, Matthew Forsberg, Donna Sonntag, Jason Cahoon, Rafet Amoor, Borom Chean, Lea Picard, Sabine Wingert, Caroline Hull, Jacki Kornbluth, Carsten Watzl, Christian Capitini, Rachit Ohri
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundDespite significant clinical breakthroughs,1 2 cellular immunotherapy remains unacceptably variable in performance3 and impractically expensive for mainstream adoption.4 These hurdles are particularly true for new cancer immunotherapies wit
Autor:
Natali Levitan, Yehezkel Sasson, Liron Danielpur, Tim Wyant, Inbar Amit, Marek Strajbl, Sharon Fischman, May Ben-Mayor, Itay Levin, Reut Barak, Aron Knickerbocker, Guy Nimrod, James Vasselli, Noam Grossman, Yanay Ofran, Olga Bluvshtein, Michael Zehnin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundIL-2 binds two forms of IL-2 receptor: a high affinity trimeric receptor composed of CD25, CD122, and CD132, and a low affinity dimeric receptor composed of CD122 and CD132. Binding to the dimeric receptors, expressed on effector cells, cau
Autor:
Lei Yang, Yun-Ting He, Song Dong, Xue-Wu Wei, Zhi-Hong Chen, Bo Zhang, Wei-Dong Chen, Xiao-Rong Yang, Fen Wang, Xue-Meng Shang, Wen-Zhao Zhong, Yi-Long Wu, Qing Zhou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
BackgroundsImmunotherapy is less effective in patients with epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC). Lower programmed cell death-ligand 1 (PD-L1) expression and tumor mutation burden (TMB) are reported to be
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Increasing evidence supports targeting the adenosine pathway in immuno-oncology with several clinical programs directed at adenosine A2 receptor (A2AR, A2BR), CD73 and CD39 in development. Through a cyclic-AMP-mediated intracellular cascade, adenosin
Autor:
Puran Zhang, Yun Gu, Hanji Fang, Yifan Cao, Jieti Wang, Hao Liu, Heng Zhang, He Li, Hongyong He, Ruochen Li, Chao Lin, Jiejie Xu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
BackgroundWith the essential role of interleukin-1 signaling in cancer-related inflammation, IL-1R1, the main receptor for both IL-1α and IL-1β, demonstrated therapeutic potential in several types of cancer, which has been put into clinical trials.
Autor:
Yosuke Dotsu, Daisuke Muraoka, Naohisa Ogo, Yudai Sonoda, Kiyoshi Yasui, Hiroyuki Yamaguchi, Hideo Yagita, Hiroshi Mukae, Akira Asai, Hiroaki Ikeda
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
BackgroundCancer immunotherapy shows insufficient efficacy for low immunogenic tumors. Furthermore, tumors often downregulate antigen and major histocompatibility complex expression to escape recognition by T cells, resulting in insufficient T cell r
Autor:
Ruhul H Choudhury, Peter Symonds, Samantha J Paston, Ian Daniels, Katherine W Cook, Mohamed Gijon, Rachael L Metheringham, Victoria A Brentville, Lindy G Durrant
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
BackgroundThe enzymatic conversion of arginine to citrulline is involved in gene and protein regulation and in alerting the immune system to stressed cells, including tumor cells. Nucleophosmin (NPM) is a nuclear protein that plays key roles in cellu
Autor:
Dipti Thakkar, Shalini Paliwal, Bhushan Dharmadhikari, Siyu Guan, Lillian Liu, Shreya Kar, Nikhil K Tulsian, Joshua J Gruber, Leah DiMascio, Konrad H Paszkiewicz, Piers J Ingram, Jerome D Boyd-Kirkup
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
BackgroundDespite significant progress in cancer immunotherapy in recent years, resistance to existing immune checkpoint therapies (ICT) is common. V-domain Ig suppressor of T cell activation (VISTA), a predominantly myeloid immune checkpoint regulat
Autor:
Boris Duchemann, Marie Naigeon, Edouard Auclin, Roberto Ferrara, Lydie Cassard, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, François-Xavier Danlos, Laura Mezquita, Caroline Caramella, Aurelien Marabelle, Benjamin Besse, Nathalie Chaput
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
BackgroundProgrammed cell death protein-1 (PD-1) expression has been associated with activation and exhaustion of both the CD4 and CD8 populations in advanced non-small cell lung cancer (aNSCLC). Nevertheless, the impact of the balance between circul